ABSTRACT
R ecreational use of heroin is dangerous in pure form, but further harm can occur from added chemicals. Adulterants are pharmacologically active additives, which may be added to improve profitability by "increasing product quantity, enhancing desired/expected drug effects, or mimicking other drug characteristics." 1, 2 The Drug Enforcement Administration has detected approximately 50 additives to heroin in the eastern United States. 3 In 2005, the first reported clenbuterol-adulterated heroin outbreak led to a multistate investigation identified by atypical reactions after heroin use. 4 A similar scenario emerged in Richmond, Virginia, in March 2015. The Virginia Department of Health (VDH) received notification from the Virginia Poison Center (VPC) of a 6-patient cluster treated for atypical, severe clinical presentations after using heroin. Symptom onset occurred immediately after use, but symptoms were uncharacteristic of heroin intoxication and raised concern that patients were exposed to heroin that was adulterated with or replaced by another substance. Outbreak control relied on collaboration between VPC, clinicians, the Division of Consolidated Laboratory Services (DCLS), the Department of Behavioral Health and Developmental Services (DB-HDS), community partners, local law enforcement, and multiple VDH divisions.
Methods
Investigation objectives were to understand outbreak extent and prevent further cases. Prevention mechanisms included informing the community of the risk and removing the causative agent from the community. The case definition from the 2005 multistate investigation was applied. 4 The investigation entailed active case finding with chart abstraction and retrospective surveillance including support from Virginia's Office of Chief Medical Examiner. VDH epidemiologists from the Division of Surveillance and Investigation (DSI) and poison center clinicians conducted interviews with hospitalized patients to collect details on symptoms and heroin exposure. Both VPC and DCLS facilitated chemical testing on patients' urine specimens. VDH collaborated with DBHDS, which notified community service boards and opiate treatment programs. DSI worked with VDH's Office of Risk Communication and Education to create a palm card with messaging regarding symptoms and guidance for getting help. Cards were disseminated by DSI, VDH's Division of Disease Prevention (DDP), and local health departments targeting persons at risk. A key component of the public health response was coordination with law enforcement to remove the dangerous substance from the community. Frequent communication among partners facilitated rapid implementation of these measures.
Results
On March 30, VPC confirmed (via the Virginia Commonwealth University toxicology laboratory) that 5 clinical samples were positive for clenbuterol, implicating it as an adulterant. Additional testing identified 13 patients who met the case definition ( Figure) . Patients' symptoms were consistent with clenbuterol exposure. 1, 4, 5 The most common clinical manifestations were hypokalemia, tachycardia, palpitations, chest pain, shortness of breath, nausea/vomiting, electrocardiogram with QT prolongation, and elevated anion gap. Ten patients required intensive care unit treatment, and 8 underwent cardiac studies to assess ischemia. No deaths were associated with this outbreak.
Ultimately, all cases could be linked to a localized area within Richmond. Interviews revealed that the majority of patients thought they received a bad batch of heroin because symptom onset occurred within seconds to hours after injecting or insufflating the presumed heroin. Patients reported they thought they were using heroin but did not feel the expected high. During the investigation, information regarding the potential supplier of the adulterated heroin was provided to VDH staff. Relevant details about this supplier were shared with local law enforcement, but no patient information was provided. After law enforcement agents became involved with the investigation, the outbreak ended.
Discussion
Adulterants added to heroin are common; heroin purity was approximately 35% in the United States during 2003-2007. 2, 6 Of concern is that certain chemicals added to heroin (eg, clenbuterol) are undetectable with routine toxicology testing, which complicates clinical management. 2 Clenbuterol, a long-acting β 2 -agonist, is a veterinary medication that is not approved by the Food and Drug Administration for human use. 7 Stimulation of β-receptors can cause refractory tachycardia, palpitations, hypokalemia, elevated lactate, metabolic acidosis, and hypotension. 1, 4, 5 Specific reasons for adding clenbuterol to heroin are unknown. Clenbuterol is "illegally sold in health food stores, by mail-order pharmacies, and on the Internet as a nutritional supplement" and is relatively inexpensive. 5 Given this accessibility, outbreaks related to clenbuterol misuse continue to pose risks.
VDH's DSI routinely performs outbreak investigations, but this atypical outbreak warranted collaboration with partners external to this division. Information sharing among the health department, local clinicians, DCLS, and VPC was integral to characterizing the outbreak. Communicating with the population at risk and their health care providers was a priority for preventing and mitigating clinical effects. ORCE, DBHDS, and DDP were key partners in message development and community outreach.
This investigation posed a unique challenge of obtaining sensitive information regarding illicit substance use. Determining a balance that maintained trust of persons at risk, while providing protection from harmful products, was imperative. Law enforcement officers had a shared interest in removing the dangerous substance from the community and were able to act on information made available by the public health investigation.
Multiple limitations relevant to this investigation were encountered. Case detection was likely underestimated because of the following: clenbuterol detection in clinical samples required specialized laboratory equipment; most physicians are unfamiliar with clenbuterol, making clinical diagnosis difficult; patients with milder presentations might not have presented for care; clinical effects of other drugs used concomitantly by a patient might have affected the clinical presentation; and patients might have altered their histories because of the sensitive nature of the implicated substance. Furthermore, multiple anecdotal reports were provided to VDH, but these potential cases could not be corroborated with medical record review. Finally, no heroin used by patients in this outbreak underwent confirmatory environmental testing.
Conclusion
Adulterants are common in illicit substances but often go undetected during routine toxicology screening. Physicians should consider adulterants in their differential diagnosis of patients presenting with atypical symptoms after illicit substance use. Poison centers have a vital role in detecting toxic exposures and are a valuable source of public health surveillance information. Because illicit substance use continues to rise, capacity to address emerging outbreaks related to adulteration becomes more pressing. The unregulated nature of illicit substance distribution and use underscores the complexity in carrying out public health investigations. Educating those at risk for exposure, clinicians, and first responders about the myriad potential consequences of adulterated drugs should be a key focus of primary and secondary prevention efforts. The rapid and collaborative public health response was critical to preventing further morbidity during this outbreak. 
Implications for Policy & Practice
The complexity of this outbreak drew attention to the importance of policies and practices that support collaboration among a diverse group of stakeholders. Early communication between public health practitioners and poison center staff led to the initial identification and investigation of the outbreak. Due to involvement of an illicit substance, outbreak control relied on input from law enforcement agents. Strengthening relationships between health departments and other institutions that might be called upon during a public health emergency increases depth and breadth of expertise. Policies that promote advance coordination of interagency collaboration can also increase timeliness of a public health response. Public health practices that emphasize communication and integrated action beyond the traditional health department boundaries are increasingly important during complex outbreaks, such as those involving illicit substances.
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